Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes

Myriad Genetics’ (MYGN) strong product portfolio raises our optimism. The company’s impressive growth strategy also encourages us. However, macroeconomic issues impede growth. The stock carries a Zacks Rank #3 (Hold) currently.Myriad Genetics has so far made significant progress with its three strategic imperatives. First, the company is developing best-in-class quality products, services and accessibility to accelerate growth and reach more patients across diverse backgrounds. Second, the company is buildi ...